STA Pharmaceutical Co Ltd (WuXi STA) disclosed on Thursday the CMC based development and manufacturing of innovative oncology drugs under a strategic partnership with Antengene Corporation, a biopharmaceutical company focused on the development of new drugs in China and the Asia-Pacific region.

Under the terms of the agreement, Antengene will receive an integrated solution in process R&D and manufacturing using the MAH scheme to accelerate new drug development from WuXi STA.

The collaboration will include both clinical stage and commercial projects, commencing with Phase II/III candidate ATG-008 and then expanding into solid tumor, hematological tumor and viral infection. WuXi STA will provide process R&D and manufacturing from APIs to drug product. Antengene and WuXi STA will explore and expand the collaboration to commercial stage assets as Antengene prepares for the commercialisation of its late-stage pipeline agents.

In addition, ATG-008 is currently in multi-regional clinical trial (MRCT) for the treatment of hepatitis B virus positive (HBV+) advanced hepatocellular carcinoma (HCC) patients (TORCH study). Patient enrollment started in July 2018, stated the partnership.

STA Pharmaceutical Co Ltd (WuXi STA) a pharmaceutical development and manufacturing company and a subsidiary of WuXi AppTec.